Ohr Pharmaceutical has announced it has added two ophthalmologists to its scientific advisory board, according to a news release.
Jeffrey S. Heier, MD, of Ophthalmic Consultants of Boston, and Daniel Roth, MD, of Retina Vitreous Center in New Jersey are joining the board, which assists in advancing Ohr's Squalamine eye drop program through clinical efficacy trials.
"We are delighted to be working with thought leaders in the retina community of the caliber of Drs. Heier and Roth," said Irach B. Taraporewala, PhD, CEO of Ohr Pharmaceutical, in the release. "The reaction of the retinal physician community to our ongoing phase II Squalamine eye drop clinical trial has been very enthusiastic. We will continue to utilize our distinguished scientific advisory board to further expand into additional neovascular ophthalmic indications."
OHR Pharmaceutical is headquartered in New York.
Related Articles on Ophthalmology:
Bascom Palmer Eye Institute to Expand FL Center in Naples
Study: Drainage Device May Replace Eye Drops for Some Glaucoma Patients
UAB Launches CDC-Funded Glaucoma Detection Program